.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022247

« Back to Dashboard
NDA 022247 describes DUAVEE, which is a drug marketed by Wyeth Pharms Pfizer and is included in one NDA. It is available from two suppliers. There are five patents protecting this drug. Additional details are available on the DUAVEE profile page.

The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.

Summary for NDA: 022247

Tradename:
DUAVEE
Applicant:
Wyeth Pharms Pfizer
Ingredient:
bazedoxifene acetate; estrogens, conjugated
Patents:5
Formulation / Manufacturing:see details

Pharmacology for NDA: 022247

Suppliers and Packaging for NDA: 022247

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL 022247 NDA Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. 0008-1123 0008-1123-12 1 POUCH in 1 CARTON (0008-1123-12) > 2 BLISTER PACK in 1 POUCH > 15 TABLET, FILM COATED in 1 BLISTER PACK
DUAVEE
bazedoxifene acetate; estrogens, conjugated
TABLET;ORAL 022247 NDA U.S. Pharmaceuticals 63539-112 63539-112-07 1 BLISTER PACK in 1 CARTON (63539-112-07) > 7 TABLET, FILM COATED in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 20MG BASE;0.45MG
Approval Date:Oct 3, 2013TE:RLD:Yes
Patent:8,815,934Patent Expiration:May 6, 2019Product Flag?YSubstance Flag?Delist Request?
Regulatory Exclusivity Expiration:Oct 3, 2016
Regulatory Exclusivity Use:NEW PRODUCT
Patent:5,998,402Patent Expiration:Apr 4, 2017Product Flag?YSubstance Flag?YDelist Request?
Patented Use:PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc